查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
結核病治療市場 - 2018-2028F 全球行業規模、佔有率、趨勢、機會和預測，按疾病類型、治療、給藥途徑、劑型、配銷通路、地區和競爭細分
市場調查報告書
商品編碼
1326475

結核病治療市場 - 2018-2028F 全球行業規模、佔有率、趨勢、機會和預測，按疾病類型、治療、給藥途徑、劑型、配銷通路、地區和競爭細分

Tuberculosis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Disease Type, By Therapy, By Route of Administration, By Dosage Form, By Distribution Channel, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 113 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

由於對尋找新的治療解決方案來對抗結核病傳播和改善患者治療效果的需求日益成長，全球結核病治療市場預計在預測期內將以令人印象深刻的速度成長。結核病 (TB) 是一種由結核分枝桿菌引起的高度傳染性且可能致命的疾病。它主要影響肺部，但也可以針對身體的其他部位，包括大腦、腎臟和脊柱。根據世界衛生組織 (WHO) 的數據，結核病是全球十大死亡原因之一，預計 2019 年有 1000 萬人罹患該病。如此高的發病率，預計對結核病治療藥物的需求繼續上升，從而推動預測期內全球結核病治療市場的成長。

耐藥性的增加

結核病是由一種可以迅速突變的細菌引起的，這種細菌會產生難以治療的耐藥菌株。耐多藥結核病（MDR-TB）和廣泛耐藥結核病（XDR-TB）是耐藥結核病的兩種形式，對全球健康構成重大挑戰。結核病耐藥菌株的出現增加了對能夠有效治療這些難治菌株的新型結核病治療藥物的需求。反過來，預計這將增加對能夠解決與結核病相關的耐藥性問題的新型療法的需求，從而推動未來幾年全球結核病治療市場的成長。在過去的十年中，開發了幾種新的結核病藥物，包括貝達喹啉、德拉馬尼和普托馬尼。貝達喹啉是一種新型藥物，已被證明可有效對抗耐藥結核病，包括耐多藥（MDR）和廣泛耐藥（XDR）結核病。德拉馬尼也被證明可以有效對抗耐藥結核病，特別是與其他結核病藥物聯合使用時。 Pretomanid 是這三種藥物中最新的一種，已被批准用於治療廣泛耐藥結核病。

結核病診斷的進展

診斷工具的進步也改善了結核病的治療。一個例子是 Xpert MTB/RIF 的使用，這是一種快速分子診斷測試，只需兩小時即可檢測出結核病和耐藥性。另一種診斷工具是 GeneXpert Omni，它可以在 90 分鐘內檢測出結核病和耐藥性。這些工具可以幫助臨床醫生做出更準確的診斷並為患者選擇最合適的治療方案。結核病診斷方法的發展也帶動了有效治療解決方案的發展，從而為未來幾年全球結核病治療市場的成長開闢了新的前景。

使用聯合療法

多年來，聯合療法在治療各種慢性和傳染病中的使用有所增加，這為新型療法的成長和開發提供了新的機遇。聯合療法的使用在結核病治療中變得越來越普遍。聯合療法涉及使用多種藥物來治療結核病，這可以改善治療結果並降低耐藥性風險。聯合療法的一個例子是使用貝達喹啉和德拉馬尼治療耐多藥結核病。另一種聯合療法稱為 BPaMZ 方案，使用貝達喹啉、普托馬尼、莫西沙星和吡嗪醯胺藥物來治療藥物敏感結核病。聯合療法在結核病治療中的使用預計將在未來幾年推動全球結核病治療市場的成長。

增加研發活動

近年來，人們重新關注結核病的研究和開發。這導致了新藥物和療法的發現，有可能改善結核病患者的治療結果。對結核病研究和開發的日益關注也增加了對新型創新結核病治療方法的需求。根據 ClinicalTrials.gov 的數據，全球約有 1,092 項處於不同開發階段的研究，旨在開發抗擊結核病的治療方法。

此外，研究仍在尋找較短療程的有效治療方法。傳統上，結核病治療涉及長期抗生素療程，永續長達兩年。然而，最近的研究表明，較短的治療方案可能同樣有效。一個例子是 BPaL 方案的使用，該方案使用貝達喹啉、普托馬尼和利奈唑胺藥物來治療耐藥結核病。該療法已被證明可以在短短六個月內有效治療結核病。反過來，預計這將支持未來幾年全球結核病治療市場的成長。

除了這些新藥和新療法外，研究人員還在探索重新利用現有藥物治療結核病的潛力。例如，2020 年《科學》雜誌上發表的一項研究發現，目前用於治療腸道感染的一種名為氯硝柳胺的藥物在實驗室實驗中顯示出殺死結核分枝桿菌的良好效果。研究人員現在計劃進行臨床試驗，以測試氯硝柳胺治療人類結核病的有效性。預計這將為未來幾年全球結核病治療市場的成長開闢新的前景。

愛滋病毒感染率不斷上升

HIV 是一種攻擊幫助身體抵抗任何類型感染的細胞的病毒，使感染 HIV 的患者更容易感染其他疾病和感染。據世界衛生組織稱，截至 2021 年，全球約有 3840 萬人感染愛滋病毒。由於免疫系統較弱，感染愛滋病毒的人患結核病的風險要高得多。據世界衛生組織稱，大約 8% 的結核病病例是愛滋病毒陽性。結核病/愛滋病毒合併感染的高患病率增加了對能夠有效治療這兩種疾病的結核病治療藥物的需求，從而支持了全球結核病治療市場的成長。

最近的發展

  • 2019年，大塚製藥有限公司的抗結核新藥Pretomanid獲得美國食品藥品監督管理局（FDA）批准，用於治療廣泛耐藥結核病。
  • 葛蘭素史克（GSK）有一個結核病藥物開發計劃，重點開發有效對抗耐藥結核病的藥物。葛蘭素史克目前正在臨床試驗中測試一種名為 GSK3036656 的藥物，該藥物在早期研究中已顯示出前景。
  • 2019年，美國食品藥品監督管理局（FDA）批准了一種名為pretomanid的新藥。 Pretomanid 是稱為 BPaL 的三藥療法的一部分，該療法還包括貝達喹啉和利奈唑胺，已被證明對治療高度耐藥的結核病非常有效。在南非進行的一項 III 期試驗中，BPaL 方案治癒了 90% 的廣泛耐藥結核病患者，這種結核病對至少四種主要結核病藥物具有耐藥性。 BPaL 治療方案也比以前的耐藥結核病護理標準更短，只需六個月而不是長達兩年。

可用的客製化：

根據給定的市場數據，TechSci Research 可根據公司的具體需求提供客製化服務。該報告可以使用以下自定義選項：

公司資訊

  • 其他市場參與者（最多五個）的詳細分析和概況分析。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 考慮學習的年份
    • 主要市場細分

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要行業合作夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量和驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球結核病治療市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 按疾病類型（活動性結核病、潛伏性結核病）
    • 按治療（一線治療、二線治療）
    • 按給藥途徑（口服、腸胃外、其他）
    • 按劑型（片劑、膠囊、注射劑、其他）
    • 按配銷通路（醫院藥房、零售藥房、網上藥房）
    • 按地區
    • 按公司分類 (2022)
  • 產品圖
    • 按疾病類型
    • 通過治療
    • 按給藥途徑
    • 按劑型分類
    • 按配銷通路
    • 按地區

第 6 章：北美結核病治療市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 按疾病類型
    • 通過治療
    • 按給藥途徑
    • 按劑型分類
    • 按配銷通路
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲結核病治療市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 按疾病類型
    • 通過治療
    • 按給藥途徑
    • 按劑型分類
    • 按配銷通路
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第 8 章：亞太地區結核病治療市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 按疾病類型
    • 通過治療
    • 按給藥途徑
    • 按劑型分類
    • 按配銷通路
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳大利亞

第 9 章：南美結核病治療市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 按疾病類型
    • 通過治療
    • 按給藥途徑
    • 按劑型分類
    • 按配銷通路
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲結核病治療市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 按疾病類型
    • 通過治療
    • 按給藥途徑
    • 按劑型分類
    • 按配銷通路
    • 按國家/地區
  • MEA：國家分析
    • 南非結核病治療機構
    • 沙烏地阿拉伯結核病治療
    • 阿拉伯聯合大公國結核病治療

第 11 章：市場動態

  • 司機
  • 挑戰

第 12 章：市場趨勢與發展

  • 近期發展
  • 併購
  • 產品發布

第 13 章：全球結核病治療市場：SWOT 分析

第 14 章：波特的五力分析

  • 行業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第15章：競爭格局

  • 商業概覽
  • 服務內容
  • 最近的發展
  • 主要人員
  • SWOT分析
    • AstraZeneca
    • Johnson & Johnson
    • Eli Lilly And Company
    • Mylan NV
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi SA
    • Novartis AG
    • Sun Pharmaceutical Industries Ltd.
    • Pfizer Inc.

第 16 章：戰略建議

簡介目錄
Product Code: 14842

Global Tuberculosis Therapeutics Market is expected to grow at an impressive rate during the forecast period on account of the growing need to find new therapeutic solutions to combat the spread of tuberculosis and improve patient outcomes. Tuberculosis (TB) is a highly infectious and potentially fatal disease caused by the bacteria Mycobacterium tuberculosis. It primarily affects the lungs but can also target other parts of the body, including the brain, kidneys, and spine. According to the World Health Organization (WHO), TB is one of the top 10 causes of death worldwide, with an estimated 10 million people falling ill with the disease in 2019. With such a high incidence rate, the demand for tuberculosis therapeutics is expected to continue to rise, thereby driving the growth of global tuberculosis therapeutics market during the forecast period.

Tuberculosis is a global health issue that affects people of all ages and from all walks of life. Despite the availability of effective treatments, the disease continues to be a major public health concern, particularly in low and middle-income countries. According to the WHO, over 90% of TB cases occur in developing countries, where access to proper healthcare and diagnostic tools is limited. As a result, there is an urgent need for effective, affordable, and accessible TB therapeutics to address the global burden of the disease. This, in turn, is expected to drive the growth of global tuberculosis therapeutics market in the coming years.

Additionally, global population is aging, and older adults are more susceptible to TB due to age-related declines in immune function. As the population continues to age, the demand for TB therapeutics that are safe and effective in older adults is expected to increase, thereby driving the growth of global tuberculosis therapeutics market.

Increasing Instances of Drug Resistance

Tuberculosis is caused by a bacterium that can mutate rapidly, leading to drug-resistant strains that are difficult to treat. Multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) are two forms of drug-resistant TB that pose a significant challenge to global health. The emergence of drug-resistant strains of TB has increased the demand for novel TB therapeutics that can effectively treat these difficult-to-treat strains. This, in turn, is expected to increase the demand for novel therapeutics that can address the issue of drug resistance related to tuberculosis, thereby fuelling the growth of global tuberculosis therapeutics market in the coming years. In the past decade, several new TB drugs have been developed, including bedaquiline, delamanid, and pretomanid. Bedaquiline is a novel drug that has been shown to be effective against drug-resistant TB, including multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB. Delamanid has also been shown to be effective against drug-resistant TB, particularly when used in combination with other TB drugs. Pretomanid, the newest of the three drugs, has been approved for the treatment of extensively drug-resistant TB.

Advancements in Tuberculosis Diagnostics

Advances in diagnostic tools have also improved the treatment of TB. One example is the use of Xpert MTB/RIF, a rapid molecular diagnostic test that can detect TB and drug resistance in just two hours. Another diagnostic tool is the GeneXpert Omni, which can detect TB and drug resistance in less than 90 minutes. These tools can help clinicians make more accurate diagnoses and choose the most appropriate treatment regimen for their patients. The development in diagnostic methods for tuberculosis is leading to the development of effective therapeutic solutions as well, thereby opening new prospects for the growth of global tuberculosis therapeutics market in the coming years.

Use of Combination Therapies

The use of combination therapies in the treatment of various chronic and infectious diseases has increased over the years, significantly opening new opportunities for the growth and development of novel therapeutics. The use of combination therapies is becoming increasingly common in the treatment of TB. Combination therapies involve the use of multiple drugs to treat TB, which can improve treatment outcomes and reduce the risk of drug resistance. One example of combination therapy is the use of bedaquiline and delamanid in the treatment of MDR-TB. Another combination therapy, called the BPaMZ regimen, uses the drugs bedaquiline, pretomanid, moxifloxacin, and pyrazinamide to treat drug-sensitive TB. The use of combination therapies in the treatment of tuberculosis is expected to drive the growth of global tuberculosis therapeutics market in the coming years.

Increased Research and Development Activities

In recent years, there has been a renewed focus on TB research and development. This has led to the discovery of new drugs and therapies that have the potential to improve treatment outcomes for patients with TB. The increased focus on TB research and development has also increased the demand for new and innovative TB therapeutics. According to clinicaltrials.gov, there are around 1,092 studies in different phases of development across the globe for developing a treatment for combating tuberculosis.

Additionally, studies are going on to find effective treatments with shorter regimens. Traditionally, TB treatment has involved a long course of antibiotics that can last for up to two years. However, recent research has shown that shorter treatment regimens may be just as effective. One example is the use of the BPaL regimen, which uses the drugs bedaquiline, pretomanid, and linezolid to treat drug-resistant TB. This regimen has been shown to be effective in treating TB in as little as six months. This, in turn, is expected to support the growth of global tuberculosis therapeutics market in the coming years.

In addition to these new drugs and regimens, researchers are also exploring the potential of repurposing existing drugs for the treatment of TB. For example, a study published in the journal Science in 2020 found that a drug called niclosamide, which is currently used to treat intestinal infections, showed promising results in killing Mycobacterium tuberculosis in laboratory experiments. The researchers are now planning to conduct clinical trials to test niclosamide's effectiveness in treating TB in humans. This is further expected to open new prospects for the growth of global tuberculosis therapeutics market in the coming years.

Growing Prevalence of HIV

HIV is a virus that attacks cells that help the body fight any kind of infection, making the patient suffering from HIV more vulnerable to other diseases and infections. According to WHO, as of 2021, there are around 38.4 million people living with HIV worldwide. People who are infected with HIV are at a much higher risk of developing TB due to their weakened immune systems. According to the WHO, around 8% of all TB cases are HIV-positive. The high prevalence of TB/HIV co-infection has increased the demand for TB therapeutics that can effectively treat both diseases, thereby supporting the growth of global tuberculosis therapeutics market.

Market Segmentation

Global Tuberculosis Therapeutics Market can be segmented by disease type, therapy, route of administration, dosage form, distribution channel, and by region. Based on disease type, global tuberculosis therapeutics market can be split into active tuberculosis and latent tuberculosis. By therapy, the global tuberculosis therapeutics market can be divided into first-line therapy and second-line therapy. Based on the route of administration, global tuberculosis therapeutics can be categorized into oral, parenteral, and others. By dosage form, the global tuberculosis therapeutics market can be segmented into tablets, capsules, injections, and others. In terms of distribution channels, the global tuberculosis therapeutics market can be grouped into hospital pharmacy, retail pharmacy, and online pharmacy. Regionally, the global tuberculosis therapeutics market can be segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa.

Market Players

AstraZeneca, Plc., Johnson & Johnson, Eli Lilly And Company, Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi SA, Novartis AG, Sun Pharmaceutical Industries Ltd., Pfizer Inc., among others, are some of the leading players operating in the global Tuberculosis Therapeutics market.

Recent Developments

  • In 2019, Otsuka Pharmaceutical Co., Ltd. received approval from the U.S. Food and Drug Administration (FDA) for a new TB drug, Pretomanid, for the treatment of extensively drug-resistant TB.
  • GlaxoSmithKline (GSK), which has a TB drug development program focused on developing drugs that are effective against drug-resistant TB. GSK is currently testing a drug called GSK3036656 in clinical trials, which has shown promise in early studies.
  • In 2019, the US Food and Drug Administration (FDA) approved a new drug called pretomanid. Pretomanid is part of a three-drug regimen called BPaL, which also includes bedaquiline and linezolid, which has been shown to be highly effective in treating highly drug-resistant forms of TB. In a phase III trial conducted in South Africa, the BPaL regimen cured 90% of patients with extensively drug-resistant TB, a form of TB that is resistant to at least four of the main TB drugs. The BPaL regimen is also shorter than the previous standard of care for drug-resistant TB, taking just six months instead of up to two years.

Report Scope:

In this report, Global Tuberculosis Therapeutics Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Tuberculosis Therapeutics Market, By Disease Type:

  • Active Tuberculosis
  • Latent Tuberculosis

Tuberculosis Therapeutics Market, By Therapy:

  • First Line Therapy
  • Second Line Therapy

Tuberculosis Therapeutics Market, By Route of Administration:

  • Oral
  • Parenteral
  • Others

Tuberculosis Therapeutics Market, By Therapy:

  • First Line Therapy
  • Second Line Therapy

Tuberculosis Therapeutics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Tuberculosis Therapeutics Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Tuberculosis Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Disease Type (Active Tuberculosis, Latent Tuberculosis)
    • 5.2.2. By Therapy (First Line Therapy, Second Line Therapy)
    • 5.2.3. By Route of Administration (Oral, Parenteral, Others)
    • 5.2.4. By Dosage Form (Tablets, Capsules, Injection, Others)
    • 5.2.5. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 5.2.6. By Region
    • 5.2.7. By Company (2022)
  • 5.3. Product Map
    • 5.3.1. By Disease Type
    • 5.3.2. By Therapy
    • 5.3.3. By Route of Administration
    • 5.3.4. By Dosage Form
    • 5.3.5. By Distribution Channel
    • 5.3.6. By Region

6. North America Tuberculosis Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Disease Type
    • 6.2.2. By Therapy
    • 6.2.3. By Route of Administration
    • 6.2.4. By Dosage Form
    • 6.2.5. By Distribution Channel
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Tuberculosis Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Disease Type
        • 6.3.1.2.2. By Therapy
        • 6.3.1.2.3. By Route of Administration
        • 6.3.1.2.4. By Dosage Form
        • 6.3.1.2.5. By Distribution Channel
    • 6.3.2. Canada Tuberculosis Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Disease Type
        • 6.3.2.2.2. By Therapy
        • 6.3.2.2.3. By Route of Administration
        • 6.3.2.2.4. By Dosage Form
        • 6.3.2.2.5. By Distribution Channel
    • 6.3.3. Mexico Tuberculosis Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Disease Type
        • 6.3.3.2.2. By Therapy
        • 6.3.3.2.3. By Route of Administration
        • 6.3.3.2.4. By Dosage Form
        • 6.3.3.2.5. By Distribution Channel

7. Europe Tuberculosis Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Disease Type
    • 7.2.2. By Therapy
    • 7.2.3. By Route of Administration
    • 7.2.4. By Dosage Form
    • 7.2.5. By Distribution Channel
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Tuberculosis Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Disease Type
        • 7.3.1.2.2. By Therapy
        • 7.3.1.2.3. By Route of Administration
        • 7.3.1.2.4. By Dosage Form
        • 7.3.1.2.5. By Distribution Channel
    • 7.3.2. Germany Tuberculosis Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Disease Type
        • 7.3.2.2.2. By Therapy
        • 7.3.2.2.3. By Route of Administration
        • 7.3.2.2.4. By Dosage Form
        • 7.3.2.2.5. By Distribution Channel
    • 7.3.3. United Kingdom Tuberculosis Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Disease Type
        • 7.3.3.2.2. By Therapy
        • 7.3.3.2.3. By Route of Administration
        • 7.3.3.2.4. By Dosage Form
        • 7.3.3.2.5. By Distribution Channel
    • 7.3.4. Italy Tuberculosis Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Disease Type
        • 7.3.4.2.2. By Therapy
        • 7.3.4.2.3. By Route of Administration
        • 7.3.4.2.4. By Dosage Form
        • 7.3.4.2.5. By Distribution Channel
    • 7.3.5. Spain Tuberculosis Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Disease Type
        • 7.3.5.2.2. By Therapy
        • 7.3.5.2.3. By Route of Administration
        • 7.3.5.2.4. By Dosage Form
        • 7.3.5.2.5. By Distribution Channel

8. Asia-Pacific Tuberculosis Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Disease Type
    • 8.2.2. By Therapy
    • 8.2.3. By Route of Administration
    • 8.2.4. By Dosage Form
    • 8.2.5. By Distribution Channel
    • 8.2.6. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Tuberculosis Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Disease Type
        • 8.3.1.2.2. By Therapy
        • 8.3.1.2.3. By Route of Administration
        • 8.3.1.2.4. By Dosage Form
        • 8.3.1.2.5. By Distribution Channel
    • 8.3.2. India Tuberculosis Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Disease Type
        • 8.3.2.2.2. By Therapy
        • 8.3.2.2.3. By Route of Administration
        • 8.3.2.2.4. By Dosage Form
        • 8.3.2.2.5. By Distribution Channel
    • 8.3.3. Japan Tuberculosis Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Disease Type
        • 8.3.3.2.2. By Therapy
        • 8.3.3.2.3. By Route of Administration
        • 8.3.3.2.4. By Dosage Form
        • 8.3.3.2.5. By Distribution Channel
    • 8.3.4. South Korea Tuberculosis Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Disease Type
        • 8.3.4.2.2. By Therapy
        • 8.3.4.2.3. By Route of Administration
        • 8.3.4.2.4. By Dosage Form
        • 8.3.4.2.5. By Distribution Channel
    • 8.3.5. Australia Tuberculosis Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Disease Type
        • 8.3.5.2.2. By Therapy
        • 8.3.5.2.3. By Route of Administration
        • 8.3.5.2.4. By Dosage Form
        • 8.3.5.2.5. By Distribution Channel

9. South America Tuberculosis Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Disease Type
    • 9.2.2. By Therapy
    • 9.2.3. By Route of Administration
    • 9.2.4. By Dosage Form
    • 9.2.5. By Distribution Channel
    • 9.2.6. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Tuberculosis Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Disease Type
        • 9.3.1.2.2. By Therapy
        • 9.3.1.2.3. By Route of Administration
        • 9.3.1.2.4. By Dosage Form
        • 9.3.1.2.5. By Distribution Channel
    • 9.3.2. Argentina Tuberculosis Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Disease Type
        • 9.3.2.2.2. By Therapy
        • 9.3.2.2.3. By Route of Administration
        • 9.3.2.2.4. By Dosage Form
        • 9.3.2.2.5. By Distribution Channel
    • 9.3.3. Colombia Tuberculosis Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Disease Type
        • 9.3.3.2.2. By Therapy
        • 9.3.3.2.3. By Route of Administration
        • 9.3.3.2.4. By Dosage Form
        • 9.3.3.2.5. By Distribution Channel

10. Middle East and Africa Tuberculosis Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Disease Type
    • 10.2.2. By Therapy
    • 10.2.3. By Route of Administration
    • 10.2.4. By Dosage Form
    • 10.2.5. By Distribution Channel
    • 10.2.6. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Tuberculosis Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Disease Type
        • 10.3.1.2.2. By Therapy
        • 10.3.1.2.3. By Route of Administration
        • 10.3.1.2.4. By Dosage Form
        • 10.3.1.2.5. By Distribution Channel
    • 10.3.2. Saudi Arabia Tuberculosis Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Disease Type
        • 10.3.2.2.2. By Therapy
        • 10.3.2.2.3. By Route of Administration
        • 10.3.2.2.4. By Dosage Form
        • 10.3.2.2.5. By Distribution Channel
    • 10.3.3. UAE Tuberculosis Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Disease Type
        • 10.3.3.2.2. By Therapy
        • 10.3.3.2.3. By Route of Administration
        • 10.3.3.2.4. By Dosage Form
        • 10.3.3.2.5. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Global Tuberculosis Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Service Offerings
  • 15.3. Recent Developments
  • 15.4. Key Personnel
  • 15.5. SWOT Analysis
    • 15.5.1. AstraZeneca
    • 15.5.2. Johnson & Johnson
    • 15.5.3. Eli Lilly And Company
    • 15.5.4. Mylan N.V.
    • 15.5.5. Teva Pharmaceutical Industries Ltd.
    • 15.5.6. Sanofi SA
    • 15.5.7. Novartis AG
    • 15.5.8. Sun Pharmaceutical Industries Ltd.
    • 15.5.9. Pfizer Inc.

16. Strategic Recommendations